中国干细胞衍生EVs治疗产品的质量评价考虑
核心信息
- 论文英文标题: Quality Evaluation Considerations for Stem Cell-Derived Extracellular Vesicles-Based Therapeutic Products in China
- 期刊: J Extracell Vesicles
- 发表年份: 2026
- DOI: 10.1002/jev2.70297
- PMID/PMCID: 42106915; PMC13157592
研究概览
Stem cell therapy is currently undergoing clinical research in China for conditions that are resistant to or incurable by traditional pharmaceutical interventions. This framework is intended to serve as a reference for researchers and developers and may help to facilitate further discussion to facilitate further discussion, thereby supporting and promoting the development, regulatory oversight and establishment of quality standards and evaluation systems for stem cell-derived EVs in China.
核心发现
Stem cell therapy is currently undergoing clinical research in China for conditions that are resistant to or incurable by traditional pharmaceutical interventions.
Stem cell-derived extracellular vesicles (EVs) exhibit therapeutic effects similar to those of their parent stem cells, positioning them as an alternative or adjunctive approach to stem cell therapy.
In recent years, given the tremendous potential for EVs in disease treatment, many researchers have focused on the development of stem cell-derived EVs and have achieved substantial progress in large-scale production and quality-related studies.
However, at present, there are no specific or targeted regulatory requirements issued by authorities in China regarding the regulation of this novel therapeutic modality or the assurance of its safety and efficacy.
Echo Biotech 角色
赵立波博士作为作者之一
关联平台: Corporate Research / Scientific Publications
关联服务与能力: Co-authored Scientific Research
关联产品或试剂: 无明确产品引用
参考文献
原始论文: Quality Evaluation Considerations for Stem Cell-Derived Extracellular Vesicles-Based Therapeutic Products in China Journal of extracellular vesicles. 2026. DOI: 10.1002/jev2.70297. PMID/PMCID: 42106915; PMC13157592.